In vitro fertilization and andrology laboratory in 2030: expert visions.


Journal

Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772

Informations de publication

Date de publication:
07 2021
Historique:
received: 12 05 2021
accepted: 12 05 2021
entrez: 21 6 2021
pubmed: 22 6 2021
medline: 6 8 2021
Statut: ppublish

Résumé

The aim of this article is to gather 9 thought leaders and their team members to present their ideas about the future of in vitro fertilization and the andrology laboratory. Although we have seen much progress and innovation in the laboratory over the years, there is still much to come, and this article looks at what these leaders think will be important in the future development of technology and processes in the laboratory.

Identifiants

pubmed: 34148588
pii: S0015-0282(21)00441-6
doi: 10.1016/j.fertnstert.2021.05.088
pii:
doi:

Types de publication

Historical Article Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

4-12

Informations de copyright

Copyright © 2021 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Alison Campbell (A)

CARE Fertility Group, Nottingham, United Kingdom.

David K Gardner (DK)

School of BioSciences, University of Melbourne, Parkville, Victoria, Australia; Melbourne IVF, East Melbourne, Victoria, Australia.

Marcos Meseguer (M)

In Vitro Fertilization Laboratory, Instituto Valenciano de Infertilidad, Reproductive Medicine Associates Valencia, Valencia, Spain; Instituto Valenciano de Infertilidad Foundation, Valencia, Spain; Health Research Institute la Fe, Valencia, Spain.

Kathleen A Miller (KA)

IVF Florida, Margate, Florida.

Markus Montag (M)

ilabcomm GmbH, Sankt Augustin, Germany.

Gianpiero D Palermo (GD)

The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, New York.

Stephanie Cheung (S)

The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, New York.

Derek Keating (D)

The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, New York.

Philip Xie (P)

The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, New York.

Zev Rosenwaks (Z)

The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, New York.

Laura Rienzi (L)

GeneraLife IVF, Clinica Valle Giulia, Rome, Italy.

Federica Innocenti (F)

GeneraLife IVF, Clinica Valle Giulia, Rome, Italy.

Danilo Cimadomo (D)

GeneraLife IVF, Clinica Valle Giulia, Rome, Italy.

Filippo Maria Ubaldi (FM)

GeneraLife IVF, Clinica Valle Giulia, Rome, Italy.

Denny Sakkas (D)

Boston IVF, Waltham, Massachusetts.

Michael J Tucker (MJ)

Shady Grove Fertility, Rockville, Maryland.

Liesl Nel-Themaat (L)

University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Carlos Simon (C)

Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain; Igenomix Foundation-Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts. Electronic address: carlos.simon@uv.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH